Richard McHale - ResMed Insider

ResMed Inc -- USA Stock  

USD 88.51  0.28  0.32%

President ? Respiratory Care

Mr. Richard McHale is President Respiratory Care of the Company. He previously served as the companys chief human resources officer, beginning in November 2013, and joined ResMed in 2011 as director of its United Kingdom business team. Mr. McHale has 25 years experience in the life sciences sector, working primarily in commercial roles within pharmaceutical, biotechnology and medical technology companies. Prior to joining ResMed, he was managing director of UCB Pharmas United Kingdom and Ireland business units. He also served as chair of the European Medicines Group and a member of the Board of Management for the Association of British Pharmaceutical Industry
Age: 52  President Since 2017      
858 836-5000  www.resmed.com
McHale holds a master?s degree in coaching psychology from the Metanoia Institute in London.

Management Efficiency

The company has Return on Asset of 8.72 % which means that on every $100 spent on asset it made $8.72 of profit. This is considered to be average in the sector. In the same way, it shows return on shareholders equity (ROE) of 18.43 % implying that it generated $18.43 on every 100 dollars invested.
The company has 1.02 B in debt with debt to equity (D/E) ratio of 49.7 . This implies that the company may be unable to create cash to meet all of its financial commitments. ResMed Inc has Current Ratio of 4.63 demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due.

Similar Executives

Showing few of many executives

PRESIDENT Since

Joseph FitzgeraldBoston Scientific Corporation
2014
Nicholas AlexosDENTSPLY SIRONA Inc
2017
Supratim BoseBoston Scientific Corporation
2011
Wendy CarruthersBoston Scientific Corporation
2012
Everett CunninghamQuest Diagnostics Incorporated
2012
Maureen MacInnisDENTSPLY SIRONA Inc
2016
Ulrich MichelDENTSPLY SIRONA Inc
2016
Andrew BaloDexCom Inc
2015
Eric ThepautBoston Scientific Corporation
2015
Desiree RallsMorrisonBoston Scientific Corporation
2017
Jeffrey MoyDexCom Inc
2011
David PierceBoston Scientific Corporation
2016
Kevin BallingerBoston Scientific Corporation
2013
Albert SterkenburgDENTSPLY SIRONA Inc
2009
Jeffrey MirvissBoston Scientific Corporation
2013
Keith DawkinsBoston Scientific Corporation
2012
Carrie MannerQuest Diagnostics Incorporated
2017
John SorensonBoston Scientific Corporation
2014
Daniel McBrideThe Cooper Companies Inc
2014
Maulik NanavatyBoston Scientific Corporation
2011
Heather AceDexCom Inc
2016

Entity Summary

ResMed Inc. designs, develops, manufactures, and markets medical devices and cloudbased software applications that diagnose, treat, and manage respiratory disorders. ResMed Inc (RMD) is traded on New York Stock Exchange in USA. It is located in CALIFORNIA, U.S.A and employs 5,250 people. ResMed is listed under Medical Equipment category by Fama And French industry classification.

Did you try this?

Run Portfolio Optimization Now
   

Portfolio Optimization

Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Hide  View All  NextLaunch Portfolio Optimization
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add ResMed Inc to your portfolio

Top Management

ResMed Inc Leadership Team
John Wareham, Director, MBA
Ronald Taylor, Director
Gary Pace, Director, Ph.D
Agnes Lee, Director
Carol Burt, Director
Rich Sulpizio, Director
Peter Farrell, Chairman, Ph.D
Jim Hollingshead, President, Ph.D
Don Darkin, President
Jack Wareham, Director
Anne Reiser, President
Karen Drexler, Director
Richard McHale, President
Donald Darkin, President
Rob Douglas, President
Christopher Roberts, Director, MBA
Chris Roberts, Director, MBA
Robert Douglas, COO
BE Farrell, Chairman
Brett Sandercock, CFO
Ron Taylor, Director
Raj Sodhi, President, MBA
David Pendarvis, Executive
Richard Sulpizio, Director
Michael Farrell, CEO, MBA

Stock Performance

ResMed Performance Indicators